Gaddis Premier Wealth Advisors LLC Makes New $701,000 Investment in Cencora, Inc. $COR

Gaddis Premier Wealth Advisors LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,076 shares of the company’s stock, valued at approximately $701,000.

Several other hedge funds have also recently bought and sold shares of COR. Oakworth Capital Inc. acquired a new position in Cencora during the fourth quarter worth $26,000. Elyxium Wealth LLC bought a new stake in shares of Cencora during the fourth quarter worth $27,000. Archer Investment Corp grew its holdings in shares of Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the last quarter. IAG Wealth Partners LLC bought a new stake in shares of Cencora during the third quarter worth $30,000. Finally, Caitlin John LLC bought a new stake in shares of Cencora during the third quarter worth $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Cencora stock opened at $274.04 on Tuesday. The business’s 50-day simple moving average is $291.82 and its 200 day simple moving average is $329.69. The stock has a market cap of $53.32 billion, a price-to-earnings ratio of 21.02, a P/E/G ratio of 1.48 and a beta of 0.59. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, research analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora declared that its board has authorized a stock repurchase plan on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio is presently 18.40%.

Analyst Ratings Changes

Several analysts have recently commented on COR shares. Robert W. Baird decreased their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Barclays increased their target price on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. UBS Group increased their target price on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Evercore set a $360.00 target price on Cencora in a report on Wednesday, April 8th. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.